Last month the Cost-Effectiveness Registry achieved a major milestone, as our team entered the 10,000th article into the database. We thank the many thousands of authors and the more than 100 Registry readers who have reviewed, collected, and analyzed the data over the years. The Registry has grown but its mission has remained the same: to identify society’s best opportunities for improving people’s health.
Happy Thanksgiving!
Peter
Peter Neumann, ScD
Director, Center for the Evaluation of Value and Risk in Health
Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
|
|
|
|
Non-Hispanic Blacks and Hispanics experience a missed or delayed diagnosis of dementia more often and have longer diagnosis delays compared to whites.
|
|
|
|
Roughly half of surveyed plan officials said they had never engaged with patients or plan enrollees when developing coverage policies.
|
|
|
|
Most of the current 23 CMS quality measures are not specific enough to assess the economic value of the practice. Aligning quality measures with cost-effectiveness evidence can improve healthcare efficiency.
|
|
|
|
COVID vaccines and therapies reduce severe illness and hence hospital utilization, thus mitigating the need for government-imposed restrictions on economic activity. During late 2020, restrictions in the US reduced consumer spending and other economic activity, costing the economy $12 billion. Health technology assessments should account for both health benefits and other societal impacts.
|
|
Updated with new drugs and decisions:
SPEC recently added 38 new drugs to the database. SPEC now includes 9000+ specialty drug coverage policies on 350 drugs along with the evidence cited by 18 of the largest US commercial payers.
New project: SPEC will soon add Medicare Advantage coverage decisions in order to examine variation in coverage.
Recently published SPEC papers:
|
|
- 187,691,880 covered lives
- 350 specialty drugs and products
- 100 product manufacturers
- 9,086 coverage decisions
- 51,222 historic coverage decisions
-
44,401 citations
|
|
|
|
|
CEVA, funded by the PhRMA Foundation, sits within CEVR and serves as a platform for innovative research on value assessment.
New publication in Value in Health:
The advent of US drug value frameworks in health care has forced a concomitant effort to develop appropriate
information displays. Researchers should formally test different formats and elements.
|
|
Cost-Effectiveness Analysis (CEA) Registry |
|
2020 Data
The CEA Registry has been updated to include analyses published through 2020 adding 996 studies, 2,370 ratios, and 3,125 utility weights to the database.
10,000th Article Uploaded
The CEA Registry reached a major milestone last month: 10,000 articles! This honor goes to a study published in Feb 2021 by Su, et al. at the First Affiliated Hospital of University of Science and Technology of China who found treatments for hepatocellular carcinoma (HCC) may be valuable with price reductions and tailored regimens.
|
|
|
|
Apply here to join CEVR's 2022 CEA Registry remote summer fellowship!
|
|
|
|
|
The Global Health CEA Registry has been updated to include all cost-per-DALY-averted studies published through 2020. It now catalogs:
- 852 studies
- 6,561 ratios
- 1,697 disability weights
The new studies cover 35 countries, 32 different diseases, and a variety of interventions.
|
|
|
Introducing our Global Health Strategic Advisory Board |
We are pleased to introduce the newly appointed members of our Global Health Strategic Advisory Board. The Board convened for an inaugural meeting on November 9, 2021 to discuss the growth and strategic direction of global health initiatives at CEVR.
Federico Augustovski, MD, PhD, Director at Instituto de Efectividad Clínica y Sanitaria, Argentina
Melanie Bertram, PhD, Health Economist at the World Health Organization
Ijeoma Edoka, PhD, Health Economist at the University of the Witwatersrand, South Africa
Shankar Prinja, PhD, Associate Professor of Health Economics at the Post Graduate Institute of Medical Education and Research, India
Yot Teerawattananon, MD, PhD, Founding leader of the Health Intervention and Technology Assessment Programme, Thailand
Anna Vassall, PhD, Director of the Centre for Health Economics in London (CHiL) at the London School of Hygiene and Tropical Medicine, United Kingdom
|
Submit your Cost-Effectiveness Analysis to CEVR’s Open-Source Model Clearinghouse
CEVR's Model Clearinghouse accepts cost-effectiveness models of any type, using any measure of health gain (e.g., DALYs, QALYs, natural units, etc.). Requirements for submission are purposefully minimal to encourage “crowd-sourced” use and adaptation of these models.
Dan Ollendorf, PhD, spoke about open-source modeling and transparency at the Society for Medical Decision Making’s annual meeting in October.
|
|
"This is a highly readable and timely guide for anyone interested in thoughtful solutions to the nation's ongoing debates about prescription drug pricing, controlling costs, and ensuring affordability while enhancing innovation to improve people's health." --Mark McClellan, Duke-Margolis Center
"I think this book is essential reading for anyone working in the areas of health economics or in the pharmaceutical or related sectors. The book is especially relevant to US readers but non-US readers will find it valuable too." Professor Brian Smith, Pragmedic
|
|
Praise for The Right Price by CEVR's own Peter J. Neumann, Joshua T. Cohen, and Daniel A. Ollendorf, Oxford University Press, 2021:
"This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade." -- Frank S. David, MD, PhD, shepherd.com
"An extremely helpful and well-sourced guide to the myriad thorny issues and history behind current drug pricing and value assessment." --Austin Frakt, Boston University School of Public Health
"This remarkable book written by the world's leading group on drug pricing explains the key issues clearly, and without compromise. If you read only one book on how to price
medicines smartly, this should be the one." --Amitabh Chandra, Harvard
Available at Amazon, Barnes & Noble, and Bookshop.org. Order direct from Oxford University Press and save 30% with promo code AMPROMD9
|
|
|
 |
Rachel Breslau, BA
Rachel graduated from Tufts University in 2021 with a BA in Economics and Political Science.
|
|
|
|
Elliott Crummer, BA
Elliott received an MA in Economics and a BS in Quantitative Economics from Miami University of Ohio.
|
|
|
|
|
Abigail Riley, BA
Abigail graduated from Boston College in 2021 with a BA in Economics and History.
|
|
|
|
Adele Levine, MPH
Adele holds a BA in Health in Human Biology from Brown University and an MPH from Boston University School of Public Health. They are currently pursuing their PhD in Health Services Research at the Boston University School of Public Health.
|
|
|
|
Julia Rucker, BA
Julia graduated from the University of New Hampshire in 2020 with a BA in Social Work, and is currently pursuing a Masters in Social Work and Public Health at Boston University.
|
|
|
Follow CEVR on Twitter and LinkedIn for the latest CEA news and insights! |
|
|
|
|
|
|
